

**Correction to the article “Prevalence of the Most Frequent Neuropsychiatric Diagnoses in Hospitalized SARS-CoV-2 Patients Evaluated by Liaison Psychiatry: Cross-Sectional Study”, Published on Acta Med Port 2022 Jun;35(6):425-432.**

**Errata ao artigo “Prevalência dos Diagnósticos Neuropsiquiátricos Mais Frequentes em Pacientes Internados com SARS-CoV-2 Avaliados por Psiquiatria de Ligação: Estudo Transversal”, Publicado em Acta Med Port 2022 Jun;35(6):425-432.**

On page 428, Table 2, column **p-value** and in the Table **description**, where it reads:

**Table 2** – Clinical characteristics and outcomes of patients with SARS-CoV-2 infection evaluated by Liaison Psychiatry

	No. (% within the group)			
	Total (n = 46)	Delirium (n = 20)	No delirium (n = 26)	p-value
<b>Risk factors for COVID-19<sup>##</sup></b>				
Cardiovascular disease <sup>\$</sup>	18 (39.1)	7 (35.0)	11 (42.3)	0.615
Cancer	6 (13.0)	2 (10.0)	4 (15.4)	0.684
Organ transplant	0 (0)	0 (0)	0 (0)	
Obesity	13 (28.3)	7 (35.0)	6 (23.0)	0.373
Sickle cell anaemia	0 (0)	0 (0)	0 (0)	
COPD	6 (13.0)	2 (10.0)	4 (15.4)	0.684
CKD	8 (17.4)	3 (15.0)	5 (19.2)	0.511
Diabetes	14 (30.4)	5 (25.0)	9 (34.6)	0.535
Any risk factor <sup>\$\$</sup>	33 (71.7)	16 (80.0)	18 (69.2)	0.410
<b>Charlson Comorbidity Index (CCI), CCI score (estimated 10-year survival)</b>				
0 (100%)	6 (13.0)	2 (10.0)	4 (15.4)	
1 (98%)	4 (8.7)	1 (5.0)	3 (11.5)	
2 (96%)	3 (6.5)	2 (10.0)	1 (3.9)	
3 (77%)	7 (15.2)	3 (15.0)	4 (15.4)	0.644
4 (53%)	4 (8.7)	3 (15.0)	1 (3.9)	
5 (21%)	5 (10.9)	2 (10.0)	3 (11.5)	
6 (2%)	4 (8.7)	3 (15.0)	1 (3.9)	
> 6 (0%)	13 (28.3)	4 (20.0)	9 (34.6)	
<b>Psychiatric history</b>				
COVID-19 symptoms <sup>  </sup>	33 (71.7)	19 (95.0)	14 (53.8)	<b>0.02</b>
ICU admission <sup>†</sup>	15 (32.6)	9 (45.0)	6 (23.1)	0.116
Days between SARS-CoV-2 positive test and LP evaluation, median (IQR)	14 (19.3)	16.50 (16.0)	8 (16.5)	<b>0.045</b>
Length of hospital stay median (IQR)	28 (34.50)	35 (34.0)	23 (36.5)	0.370
<b>Outcomes</b>				
Death	5 (10.9)	3 (15.0)	2 (7.7)	0.640 <sup>††</sup>
Discharged	40 (87.0)	17 (85.0)	23 (88.5)	1 <sup>††</sup>
Lost to follow-up	1 (2.17)	0 (0)	1 (3.8)	1 <sup>††</sup>

<sup>##</sup>: Risk factors for severe COVID-19 illness as defined by CDC in March 2020<sup>18</sup>; <sup>\$</sup>: Severe cardiovascular disease, including congestive heart failure, coronary artery disease or cardiomyopathy; <sup>\$\$</sup>: Presence of any of the previous risk factors; <sup>||</sup>: Cough, dyspnoea, and fever; <sup>†</sup>: Admission to intensive care unit (ICU) during hospitalisation; <sup>\*\*</sup>: Chi-squared test;

<sup>††</sup>: Fisher's Exact test.

COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; IQR: Inter-Quartile Range; LP: Liaison Psychiatry

It should read:

**Table 2 – Clinical characteristics and outcomes of patients with SARS-CoV-2 infection evaluated by Liaison Psychiatry**

	No. (% within the group)			
	Total (n = 46)	Delirium (n = 20)	No delirium (n = 26)	p-value
<b>Risk factors for COVID-19<sup>##</sup></b>				
Cardiovascular disease <sup>\$</sup>	18 (39.1)	7 (35.0)	11 (42.3)	0.615**
Cancer	6 (13.0)	2 (10.0)	4 (15.4)	0.684**
Organ transplant	0 (0)	0 (0)	0 (0)	
Obesity	13 (28.3)	7 (35.0)	6 (23.0)	0.373**
Sickle cell anaemia	0 (0)	0 (0)	0 (0)	
COPD	6 (13.0)	2 (10.0)	4 (15.4)	0.684**
CKD	8 (17.4)	3 (15.0)	5 (19.2)	0.511**
Diabetes	14 (30.4)	5 (25.0)	9 (34.6)	0.535**
Any risk factor <sup>§§</sup>	33 (71.7)	16 (80.0)	18 (69.2)	0.410**
<b>Charlson Comorbidity Index (CCI), CCI score (estimated 10-year survival)</b>				
0 (100%)	6 (13.0)	2 (10.0)	4 (15.4)	
1 (98%)	4 (8.7)	1 (5.0)	3 (11.5)	
2 (96%)	3 (6.5)	2 (10.0)	1 (3.9)	
3 (77%)	7 (15.2)	3 (15.0)	4 (15.4)	0.644††
4 (53%)	4 (8.7)	3 (15.0)	1 (3.9)	
5 (21%)	5 (10.9)	2 (10.0)	3 (11.5)	
6 (2%)	4 (8.7)	3 (15.0)	1 (3.9)	
> 6 (0%)	13 (28.3)	4 (20.0)	9 (34.6)	
<b>Psychiatric history</b>				
COVID-19 symptoms <sup>  </sup>	33 (71.7)	19 (95.0)	14 (53.8)	0.02**
ICU admission <sup>†</sup>	15 (32.6)	9 (45.0)	6 (23.1)	0.116**
Days between SARS-CoV-2 positive test and LP evaluation, median (IQR)	14 (19.3)	16.50 (16.0)	8 (16.5)	0.045*
Length of hospital stay median (IQR)	28 (34.50)	35 (34.0)	23 (36.5)	0.370*
<b>Outcomes</b>				
Death	5 (10.9)	3 (15.0)	2 (7.7)	0.640††
Discharged	40 (87.0)	17 (85.0)	23 (88.5)	1††
Lost to follow-up	1 (2.17)	0 (0)	1 (3.8)	1††

**##:** risk factors for severe COVID-19 illness as defined by CDC in March 2020<sup>15</sup>; **\$:** severe cardiovascular disease, including congestive heart failure, coronary artery disease or cardiomyopathy; **§§:** presence of any of the previous risk factors; **||:** cough, dyspnoea, and fever; **†:** admission to intensive care unit (ICU) during hospitalisation; **\*\*:** chi-square test; **††:** Fisher's Exact test; **\*:** Mann-Whitney test

COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; IQR: Inter-Quartile Range; LP: Liaison Psychiatry

Article published with errors:

<https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/16410>

Na página 428, Table 2, coluna **p-value** e na **legenda** da Tabela, onde se lê:

**Table 2** – Clinical characteristics and outcomes of patients with SARS-CoV-2 infection evaluated by Liaison Psychiatry

	Total (n = 46)	Delirium (n = 20)	No delirium (n = 26)	p-value
<b>Risk factors for COVID-19<sup>##</sup></b>				
Cardiovascular disease <sup>§</sup>	18 (39.1)	7 (35.0)	11 (42.3)	0.615
Cancer	6 (13.0)	2 (10.0)	4 (15.4)	0.684
Organ transplant	0 (0)	0 (0)	0 (0)	
Obesity	13 (28.3)	7 (35.0)	6 (23.0)	0.373
Sickle cell anaemia	0 (0)	0 (0)	0 (0)	
COPD	6 (13.0)	2 (10.0)	4 (15.4)	0.684
CKD	8 (17.4)	3 (15.0)	5 (19.2)	0.511
Diabetes	14 (30.4)	5 (25.0)	9 (34.6)	0.535
Any risk factor <sup>§§</sup>	33 (71.7)	16 (80.0)	18 (69.2)	0.410
<b>Charlson Comorbidity Index (CCI), CCI score (estimated 10-year survival)</b>				
0 (100%)	6 (13.0)	2 (10.0)	4 (15.4)	
1 (98%)	4 (8.7)	1 (5.0)	3 (11.5)	
2 (96%)	3 (6.5)	2 (10.0)	1 (3.9)	
3 (77%)	7 (15.2)	3 (15.0)	4 (15.4)	0.644
4 (53%)	4 (8.7)	3 (15.0)	1 (3.9)	
5 (21%)	5 (10.9)	2 (10.0)	3 (11.5)	
6 (2%)	4 (8.7)	3 (15.0)	1 (3.9)	
> 6 (0%)	13 (28.3)	4 (20.0)	9 (34.6)	
<b>Psychiatric history</b>				
<b>COVID-19 symptoms<sup>  </sup></b>	33 (71.7)	19 (95.0)	14 (53.8)	<b>0.02</b>
<b>ICU admission<sup>†</sup></b>	15 (32.6)	9 (45.0)	6 (23.1)	0.116
<b>Days between SARS-CoV-2 positive test and LP evaluation, median (IQR)</b>	14 (19.3)	16.50 (16.0)	8 (16.5)	<b>0.045</b>
<b>Length of hospital stay median (IQR)</b>	28 (34.50)	35 (34.0)	23 (36.5)	0.370
<b>Outcomes</b>				
Death	5 (10.9)	3 (15.0)	2 (7.7)	0.640 <sup>††</sup>
Discharged	40 (87.0)	17 (85.0)	23 (88.5)	1 <sup>††</sup>
Lost to follow-up	1 (2.17)	0 (0)	1 (3.8)	1 <sup>††</sup>

**##:** Risk factors for severe COVID-19 illness as defined by CDC in March 2020<sup>15</sup>; **§:** Severe cardiovascular disease, including congestive heart failure, coronary artery disease or cardiomyopathy; **§§:** Presence of any of the previous risk factors; **||:** Cough, dyspnoea, and fever; **†:** Admission to intensive care unit (ICU) during hospitalisation; **\*\*:** Chi-squared test; **††:** Fisher's Exact test.

COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; IQR: Inter-Quartile Range; LP: Liaison Psychiatry

Deverá ler-se:

**Table 2 – Clinical characteristics and outcomes of patients with SARS-CoV-2 infection evaluated by Liaison Psychiatry**

	No. (% within the group)			<i>p</i> -value
	Total (n = 46)	Delirium (n = 20)	No delirium (n = 26)	
<b>Risk factors for COVID-19<sup>‡‡</sup></b>				
Cardiovascular disease <sup>§</sup>	18 (39.1)	7 (35.0)	11 (42.3)	0.615**
Cancer	6 (13.0)	2 (10.0)	4 (15.4)	0.684**
Organ transplant	0 (0)	0 (0)	0 (0)	
Obesity	13 (28.3)	7 (35.0)	6 (23.0)	0.373**
Sickle cell anaemia	0 (0)	0 (0)	0 (0)	
COPD	6 (13.0)	2 (10.0)	4 (15.4)	0.684**
CKD	8 (17.4)	3 (15.0)	5 (19.2)	0.511**
Diabetes	14 (30.4)	5 (25.0)	9 (34.6)	0.535**
Any risk factor <sup>§§</sup>	33 (71.7)	16 (80.0)	18 (69.2)	0.410**
<b>Charlson Comorbidity Index (CCI), CCI score (estimated 10-year survival)</b>				
0 (100%)	6 (13.0)	2 (10.0)	4 (15.4)	
1 (98%)	4 (8.7)	1 (5.0)	3 (11.5)	
2 (96%)	3 (6.5)	2 (10.0)	1 (3.9)	
3 (77%)	7 (15.2)	3 (15.0)	4 (15.4)	0.644††
4 (53%)	4 (8.7)	3 (15.0)	1 (3.9)	
5 (21%)	5 (10.9)	2 (10.0)	3 (11.5)	
6 (2%)	4 (8.7)	3 (15.0)	1 (3.9)	
> 6 (0%)	13 (28.3)	4 (20.0)	9 (34.6)	
<b>Psychiatric history</b>				
<b>COVID-19 symptoms<sup>  </sup></b>	33 (71.7)	19 (95.0)	14 (53.8)	0.02**
<b>ICU admission<sup>†</sup></b>	15 (32.6)	9 (45.0)	6 (23.1)	0.116**
<b>Days between SARS-CoV-2 positive test and LP evaluation, median (IQR)</b>	14 (19.3)	16.50 (16.0)	8 (16.5)	0.045*
<b>Length of hospital stay median (IQR)</b>	28 (34.50)	35 (34.0)	23 (36.5)	0.370*
<b>Outcomes</b>				
Death	5 (10.9)	3 (15.0)	2 (7.7)	0.640††
Discharged	40 (87.0)	17 (85.0)	23 (88.5)	1††
Lost to follow-up	1 (2.17)	0 (0)	1 (3.8)	1††

<sup>‡‡</sup>: risk factors for severe COVID-19 illness as defined by CDC in March 2020<sup>16</sup>; <sup>§</sup>: severe cardiovascular disease, including congestive heart failure, coronary artery disease or cardiomyopathy; <sup>§§</sup>: presence of any of the previous risk factors; <sup>||</sup>: cough, dyspnoea, and fever; <sup>†</sup>: admission to intensive care unit (ICU) during hospitalisation; \*\*: chi-square test; ††: Fisher's Exact test; †: Mann-Whitney test

COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; IQR: Inter-Quartile Range; LP: Liaison Psychiatry

Artigo publicado com erros:

<https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/16410>



<https://doi.org/10.20344/amp.18534>